Diseases that Harm Require Therapies that Harm Less

---Sir William Osler(1849-1919)
Home > News > Newsletter
ISMIVS Newsletter July, 2020
Newsletter 2020 July
2020 年 7 月简报
About Us 国际微无创医学会简介
The International Society of Minimally Invasive and Virtual Surgery (ISMIVS, previously known as International Society of Minimally Invasive and Noninvasive Medicine) was founded in July 2013 at the gala of the 1st Yangtze International Summit of Minimally Invasive and Noninvasive Medicine in Chongqing, China. ISMIVS envisions to accelerating the progress in minimally invasive and noninvasive medicine by promoting research, education, communication, and international collaboration.
国际微无创医学会(ISMIVS)是在 2013 年 7 月在中国重庆召开的第一届国际微无创医学长江高峰论坛上宣布成立的,旨在通过学术研究、教育、交流以及国际合作加快微无创医学的发展。
Become a member 注册成为会员
The Personality in the Medical Education World 医学教育界的大人物
From the July issue of our ISMIVS Newsletter, we would like to introduce some pioneers in the field of minimally-invasive and noninvasive medicine. They are not only prestigious in their field but also willing to share their experience and ideas with younger doctors, hence making great contribution to medical education. In this issue, we are going to introduce Prof. LEE Chyi-Long and share with you one of his teaching videos.
从 7 月刊开始,国际微无创医学会(ISMIVS)将为大家介绍微无创医学领域的一些领军人物。他们不仅在各自的领域享负盛名,而且非常乐意与年轻医生分享他们的经验、理念和想法,从而为医学教育做出了巨大的贡献。本月刊要介绍的医学教育界的大人物就是李奇龙教授,其教学视频请见文末。
Professor LEE Chyi-Long
李奇龙教授
Professor Lee is currently a Professor in Chang Gung University. He serves as the Chairperson of the Board of Trustees of the Asia-Pacific Association for Gynecologic Endoscopy and Minimally Invasive Therapy (APAGE). He specializes in infertility treatment, IVF, malignant tumors and genital tract malformations. Every year, Prof. Lee performs over 700 operations, with a solid 60% success rate for IVF patients and a 92.78% ± 3.06% survival rate for laparoscopic radical hysterectomy for cervical cancer in a median 92.1-month follow-up.
Read More
李奇龙教授现任亚太妇产科内视镜暨微创治疗医学会(APAGE)创会理事长,同时也是长庚大学医学系教授。专精于不孕症治疗、体外受精(IVF)、恶性肿瘤和生殖道畸形。每年手术量达 700 余例,IVF 成功率达 60%,腹腔镜下子宫全切术治疗宫颈癌术后中位随访 92.1 个月的生存率为 92.78% ± 3.06%。
As a speaker and organizer of numerous local and international conferences and workshops, Prof. Lee is dedicated to the development and education of minimally invasive surgery in the Asia-Pacific regions and he has trained 194 doctors from 22 countries and regions, who have later become leading OBGYNs in their local areas.
李奇龙教授参会无数国内外重要会议,受邀担任大会主场次演讲者。除此之外,每年在亚太地区举办过多场国际大型会议及手术研讨会。为微创手术的推广及发展不遗余力,已培养来自 22 个国家及地区的 194 名医生,受训医生后来皆成为当地的妇产科名医。
Prof. Lee has published more than 200 papers, 7 medical textbooks and 9 books on health education. As of February, 2020, he has delivered 709 invited speeches at home and abroad. He was elected as an Honorary Fellow of European Society for Gynaecological Endoscopy (ESGE), Chinese Obstetricians and Gynecologists Association (COGA) and Philippine Society for Gynecologic Endoscopy (PSGE) respectively in recognition of his professionalism and significant contribution to gynecologic endoscopic surgery and minimally invasive therapy.
李奇龙教授已发表 200 余篇论文,并已出版 7 本医学教科书以及 9 本健康教育书籍。截至到 2020 年 2 月底,已在国内外受邀发表 709 次演讲。此外,李奇龙教授还是欧洲妇科内镜学会(ESGE)、中国医师协会妇产科医师分会(COGA)、菲律宾妇产科内视镜医学会(PSGE)的荣誉会员。
Video presentation: Excision of Uterosacral Ligament Endometriosis and Adenomyomectomy.
请点击以下链接观看教学视频:子宫骶韧带上的子宫内膜异位症切除术及子宫腺肌瘤剔除术.
https://vimeo.com/402453818/f8c1ef624b or http://live.99zigong.com/Html/video/857.html
For more information about Prof. Lee and gynecologic endoscopic surgery, please follow:
如需了解更多有关李奇龙教授及妇科腔镜手术的信息,请关注:
Facebook 李奇龙教授脸书: Dr.ChyiLong Lee
Weibo 李奇龙教授微博: https://www.weibo.com/3824990076/
APAGE Facebook 学会脸书: https://www.facebook.com/apage2003/
News 新闻
APAGE - ISMIVS HIFU (AIH) Webinar 2020
亚太妇产科内视镜暨微创治疗医学会(APAGE)与国际微无创医学会(ISMIVS)联合会议
暨2020高强度聚焦超声消融技术手术(HIFU)线上系列研讨会
To foster academic exchanges in the new field of minimally invasive and noninvasive surgeries, the Asia-Pacific Association for Gynecologic Endoscopy and Minimally Invasive Therapy (APAGE) and the International Society of Minimally Invasive and Virtual Surgery (ISMIVS) have co-organized an APAGE - ISMIVS HIFU (AIH) Webinar Series, which consisted of four episodes starting from June 11, 2020 to July 23, 2020.
为促进微无创手术领域的学术交流,亚太妇产科内视镜暨微创治疗医学会(APAGE)与国际微无创医学会(ISMIVS)已携手举办联合会议暨 2020 高强度聚焦超声消融技术手术(HIFU)线上系列研讨会,总计 4 场学术盛宴,已于 2020 年 6 月 11 日至 7 月 23 日期间成功召开。
Chaired by Prof. LEE Keen Whye (Singapore), a Founding Member of APAGE, this Webinar features renowned OBGYNs in the Asia-Pacific region on their views of the management of uterine fibroids and adenomyosis as well as HIFU experts on their ideas of HIFU treatment. Here are the links for your playback:
本次线上系列研讨会由 APAGE 创始董事李建威教授(新加坡)担任会议主席,邀请了亚太地区众多妇产科名医以及 HIFU 专家参与,分享其对子宫肌瘤、子宫腺肌症、HIFU 治疗的看法。以下是四场会议的视频回放链接:
Episode 1 第一场:
https://www.youtube.com/watch?v=UJlm-HFzqMI or http://live.99zigong.com/Html/video/775.html
Episode 2 第二场:
https://www.youtube.com/watch?v=SMhxXxCWRrw or http://live.99zigong.com/Html/video/787.html
Episode 3 第三场:
https://www.youtube.com/watch?v=4DABS_EWljg or http://live.99zigong.com/Html/video/827.html
Episode 4 第四场:
https://www.youtube.com/watch?v=5JeQ0RJIy3E or http://live.99zigong.com/Html/video/837.html
The 8th APAGE-Tongji Gynecologic Minimally Invasive Surgery and Oncology Forum
第八届亚太-同济妇科微创医学与肿瘤论坛正在进行中
Consisting of four sessions, the 8th APAGE-Tongji Gynecologic Minimally Invasive Surgery and Oncology Forum on the standardization of cervical cancer surgery is taking place online from 18 July 2020 to 8 August, 2020. The Forum is jointly organized by the Asia-Pacific Association for Gynecologic Endoscopy & Minimally Invasive Therapy (APAGE) and Shanghai Tenth People's Hospital of Tongji University. (Conference language: mainly in Chinese and some in English)
第 8 届亚太-同济妇科微创医学与肿瘤论坛:宫颈癌手术标准化与规范化正于 2020 年 7 月 18 日至 8 月 8 日期间召开。本届线上论坛共 4 期,由亚太妇产科内视镜暨微创治疗医学会(APAGE)与同济大学附属第十人民医院等单位联合举办。(会议语言:中文为主,部分讲课专家英文授课。)
To attend the 4th session on August 8 or review the previous three sessions, please click the link below to register:
欲参加本届论坛第 4 期或回顾前三期会议,请点击下方链接注册:
http://live.1mice.net/Home/register/index/vid/32.html
APAGE Minimally Invasive Surgery Webinar
亚太微创手术系列线上会议
The APAGE Minimally Invasive Surgery Webinar Series is taking place at 5:00 pm (Beijing Time) on July 30, August 27, and September 10, 2020 respectively. To review the first webinar on hysteroscopic shaving technique on July 30 or attend the following webinars. Please click the link below to register:
亚太微创手术系列线上会议(3 场学术盛宴)正在召开,会议时间分别为北京时间 2020 年 7 月 30 日、8 月 27 日以及 9 月 10 日下午 5 点。欲回顾 7 月 30 日第一期会议——宫腔镜剔除术或参加下期会议,欢迎点击下方链接注册(请使用Chrome或Firefox浏览器打开):
https://onlinexperiences.com/scripts/Server.nxp?LASCmd=AI:4;F:QS!10100&ShowUUID=6DF51FBD-E49C-45C6-8BE9-96B60B36C09F
Playback of TAMIG&APAGE First Web-meeting on May 16, 2020
第一届子宫全切根治宫颈癌标准化线上会议
Here's the playback of the 1st International ONLINE Conference on Standardization of Radical Hysterectomy for Cervical Cancer: https://www.youtube.com/playlist?list=PL7KWadgXHRb2HAh6hBwrXg6jhC6V_Y2P-
2020 年 5 月 16 日,台湾妇产科内视镜暨微创医学会(TAMIG)联合亚太妇产科内视镜暨微创治疗医学会(APAGE)举办了第一届子宫全切根治宫颈癌标准化线上会议。欲了解会议详情,请点击上方链接。
Tech Update 微无创技术新进展
Radiofrequency combined with immunomodulation for hepatocellular carcinoma:
State of the art and innovations
射频消融联合免疫调节疗法治疗肝癌的最新进展与创新
Recently a state-of-the-art clinical study reviewed that the combination treatment of radiofrequency ablation (RFA) with immunotherapy had a good effect on hepatocellular carcinoma (HCC). This treatment strategy has emerged as a promising approach to activate and potentialize local and systemic immune responses. It has potential to reinstate anti-tumor immunity in HCC through increase in antitumor T cell response. The approach seems quite pragmatic in limiting the recurrence and improving survival rates compared to RFA alone for HCC patients. This review highlighted scientific evidence that supports the current recommendations for pre-clinical studies, and discussed the need for further research on this topic.
近期一项最新临床研究显示,射频消融(RFA )联合免疫疗法治疗肝癌效果良好。该联合治疗方案有望激发患者的局部和全身免疫反应, 可增强 T 细胞的抗肿瘤反应从而使肝癌患者恢复抗肿瘤免疫功能。对比单独 RFA 治疗肝癌患者,该联合治疗在抑制肝癌复发、提高患者生存率方面都有着实际效果。本篇综述强调了支持目前对临床前研究的建议的科学论据,并讨论了进一步研究该治疗方案的必要性。
Read More
--------------------------------------------------------
Recommendations for the surgical management of gynecological cancers
during the COVID-19 pandemic - FRANCOGYN group for the CNGOF
法国妇产科医师协会 FRANCOGYN 小组发布:新冠病毒大流行期间的妇癌手术管理建议
If a patient with a gynecologic cancer presents with COVID-19, surgical management should be postponed for at least 15 days. For cervical cancer, radiotherapy and concomitant radio-chemotherapy could replace surgery as first-line treatment. For advanced ovarian cancers, neoadjuvant chemotherapy should be preferred over primary cytoreduction surgery. For early stage endometrial cancer of low and intermediate preoperative ESMO risk, hysterectomy with bilat eral adnexectomy combined with a sentinel lymph node procedure is recommended. During the COVID-19 pandemic, management of a patient with cancer should be adapted to limit the risks associated with the virus without incurring loss of chance.
妇癌患者若感染新冠病毒(COVID-19),手术治疗应至少推迟 15 天方可进行。针对宫颈癌,放射治疗以及放射化疗联合疗法可替代一线手术治疗。对于晚期卵巢癌, 应优先选择新辅助化疗,而非肿瘤细胞减灭术。在管理早期子宫内膜癌合并中低术前风险(根据欧洲肿瘤学会(ESMO)发布的指南评估)时,推荐行子宫全切、双侧附件切除并联合前哨淋巴结切除。新冠疫情大流行期间,癌症患者的管理应遵循降低病毒感染风险同时把握治疗时机的原则。
Read More
--------------------------------------------------------
Comparison of high-intensity focused ultrasound ablation and secondary myomectomy for
recurrent symptomatic uterine fibroids following myomectomy: a retrospective study
对比高强度聚焦超声消融和肌瘤剔除术治疗剔除术后复发的、有症状的肌瘤:回顾性研究
A retrospective study by Chinese PLA General Hospital, comparing high-intensity focused ultrasound ablation (HIFUA) and secondary myomectomy for women with recurrent symptomatic uterine fibroids following myomectomy, showed that HIFUA of recurrent symptomatic uterine fibroids offers comparable long-term alleviation of symptoms with longer time interval to reintervention and fewer adverse events compared with secondary myomectomy.
中国人民解放军总医院近期在英国妇产科杂志(BJOG)上发表的一篇回顾性研究对比了高强度聚焦超声消融(HIFUA)和肌瘤剔除术治疗剔除术后复发的、有症状的肌瘤的情况,表明高强度聚焦超声消融不仅可获得与二次肌瘤剔除术相当的长期症状缓解,而且需要再干预的间隔时间更长,不良反应更低。
Read More
International Guidelines on HIFU in OBGYN 国际妇科领域与HIFU相关的临床指南
HIFU included into the KSOG Guidelines for uterine fibroids and adenomyosis
HIFU 进入大韩妇产科学会(KSOG)2016《高强度超声波聚焦术(HIFU) 医疗指南》
On July 15, 2016, the Korean Society of Obstetrics and Gynecology published medical guidelines on high-intensity focused ultrasound (HIFU), including MRI-Guided Focused Ultrasound Ablation and Ultrasound-guided High Intensity Focused Ultrasound. It specifies the key indications of HIFU: premenopausal patients of 18 years of age or older, with uterine fibroids or adenomyosis accompanied by symptoms such as hemorrhage, anemia and dysmenorrheal.
2016 年 7 月 15 日,大韩妇产科学会发布《高强度超声波聚焦术(HIFU)医疗指南》,纳入了磁共振引导下的高聚焦超声波消融术和超声波引导下的高强度超声波聚焦术。《指南》明确了 HIFU 的主要适应症:以 18 岁以上,伴着出血、贫血、痛经等症状的子宫肌瘤或子宫腺肌病的闭经前患者为对象。
Read More
--------------------------------------------------------
HIFU included into the 2017 Chinese Expert Consensus
on the Diagnosis and Treatment of Uterine Fibroids
高强度聚焦超声消融术进入 2017《子宫肌瘤的诊治中国专家共识》
In December, 2017, the latest Chinese Expert Consensus on the Diagnosis and Treatment of Uterine Fibroids was published by the Expert Panel on the Chinese Journal of Obstetrics and Gynecology, introducing the high intensity focused ultrasound ablation (HIFUA or ultrasound ablation) as one of the minimally-invasive and non-invasive surgeries or other treatment alternatives for uterine fibroids as well as the indications, contraindications and complications for HIFUA. Indications for HIFUA are largely the same as for open surgeries. However, HIFUA is recommended as the preferred choice for patients with desire of uterus-sparing, and for those who are intolerant of or unwilling to undergo open surgeries.
2017 年 12 月,子宫肌瘤的诊治中国专家共识专家组在中华妇产科杂志发表最新的《子宫肌瘤的诊治中国专家共识》,将高强度聚焦超声消融(HIFUA)作为子宫肌瘤的微无创手术治疗或其他替代治疗方式的一种纳入其中,并介绍了高强度聚焦超声消融的适应症、禁忌症、并发症。高强度聚焦超声消融的适应证与手术治疗的适应症基本相同,适用于要求保留子宫者,尤其适合不能耐受或不愿意手术治疗者。
Read More
isminim@isminim.org ISMIVS
+86 23 67886199 ISMIVS
www.haifumedical.com ISMIVS 2020
No.1 Qingsong Rd, Renhe, Yubei Dist, Chongqing 401121, China

ISMIVS

ISMIVS

+86 23 67886199

ISMIVS 2020